2025 COMB丨Professor Peng Yuan: Multi-Gene Testing Drives Personalized Treatment and Illuminates a New Era in Precision Breast Cancer Care
Editor’s Note: The 8th Conference on Oncology Precision Medicine and the 11th Conference on Individualized Therapy for Breast Cancer were recently held in Beijing, jointly organized by the Beijing Breast…
Professor Ping Zhang at COMB 2025: Breaking Through Endocrine Resistance—New Precision Pathways for HR+/HER2- Breast Cancer
Editor’s Note: Endocrine resistance is one of the major challenges in the treatment of HR+/HER2- breast cancer. At the 8th Conference on Oncology Precision Medicine and the 11th Conference on…
Academician Xishan Hao: The Mission of Advancing Chinese Oncology and Building Academic Journal
Editor’s Note: With China’s rapidly aging population, cancer prevention and treatment face new challenges and opportunities. As the birthplace of modern oncology in China, Tianjin Medical University Cancer Institute and…
Professor Xiaowei Qi: Preferred Neoadjuvant Strategies in HER2-Positive Breast Cancer and Breakthrough Directions in TNBC Immunotherapy
Editor’s Note: The 2025 Summer Breast Cancer Forum · Northern Salon was held in Qingdao, Shandong, from August 8–10. Upholding the spirit of “learning and innovation” and the tradition of…
Professors Xuening Ji & Yuhua Song: Rescue Therapy in TNBC—Which Immunotherapy Combination Should Be Preferred?
Editor’s Note: In the rescue treatment of advanced triple-negative breast cancer (TNBC), should immunotherapy be combined with chemotherapy or with antibody–drug conjugates (ADCs)? At the 2025 Summer Breast Cancer Forum…
Professors Li Wang & Jianbin Li: Choosing Adjuvant Therapy for Intermediate-Risk HR+ Early Breast Cancer
Editor’s Note: For patients with intermediate-risk hormone receptor–positive early breast cancer (HR+ EBC), should adjuvant therapy prioritize chemotherapy plus an aromatase inhibitor (AI), or an AI combined with a CDK4/6…
Professors Bin Song & Yuan Peng: How Should We Choose CDK4/6 Inhibitors for Adjuvant Endocrine Therapy Intensification?
For patients with hormone receptor–positive (HR+) early breast cancer, when intensifying adjuvant endocrine therapy with a CDK4/6 inhibitor, should abemaciclib or ribociclib be preferred? At the 2025 Summer Breast Cancer Forum · Northern Salon, Professors Bin Song of Shanxi Bethune Hospital and Yuan Peng of Peking University People’s Hospital debated this question during the “Debate” session. Here, in Oncology Frontier’s “In-Depth” column, they share their perspectives supported by evidence.
The 28th CSCO Annual Meeting Opens in Jinan
This September, the city of Jinan welcomed one of China’s most prestigious academic events in oncology. The 28th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO 2025) officially opened on the morning of September 11th, gathering experts, clinicians, researchers, and industry representatives from across the country. Multiple academicians and internationally renowned oncologists attended the ceremony to discuss new progress in cancer prevention and treatment under the theme “Standardized Treatment, Innovation-Driven Leadership”—together charting a new global blueprint for the fight against cancer.